Atea Pharmaceuticals, Inc.
AVIRNASDAQHealthcare● Active
$4.32
+$0.07(+1.65%)
Market Cap$345717068
P/E Ratio—
52W High$6.45
52W Low$2.78
Atea Pharmaceuticals, Inc. (AVIR) · Cash Flow
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · AVIR · as of 2026-06-10
Financial statements
Operating CF · CapEx · Free Cash Flow
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | ($0.16B) | ($0.17B) | ($0.14B) | ($0.12B) | $0.12B |
| Depreciation & Amort. | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Stock-Based Comp. | $0.02B | $0.05B | $0.05B | $0.05B | $0.04B |
| Change in Working Capital | $0.02B | ($0.01B) | $0.02B | ($0.05B) | ($0.25B) |
| Net Cash from Operations | ($0.13B) | ($0.14B) | ($0.09B) | ($0.12B) | ($0.09B) |
| Investing Activities | |||||
| Capital Expenditure | $0.00B | $0.00B | $0.00B | ($0.00B) | ($0.00B) |
| Purchases of Investments | ($0.28B) | ($0.46B) | ($0.56B) | ($0.55B) | $0.00B |
| Sales of Investments | $0.47B | $0.52B | $0.60B | $0.09B | $0.00B |
| Net Cash from Investing | $0.19B | $0.06B | $0.04B | ($0.46B) | ($0.00B) |
| Financing Activities | |||||
| Common Stock Repurchased | ($0.03B) | $0.00B | $0.00B | $0.00B | $0.00B |
| Dividends Paid | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Debt Issued / Repaid | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Net Cash from Financing | ($0.03B) | $0.00B | $0.00B | $0.00B | $0.00B |
| Free Cash Flow | |||||
| Free Cash Flow | ($0.13B) | ($0.14B) | ($0.09B) | ($0.12B) | ($0.09B) |
| FCF Margin %(computed) | — | — | — | — | -24.76% |
Data source: Financial Modeling Prep · Last updated: 2026-06-10 · USD · B
Explore more Atea Pharmaceuticals, Inc. data
About Atea Pharmaceuticals, Inc. (AVIR) Cash Flow Statement
Atea Pharmaceuticals, Inc. generated operating cash flow of ($0.13B) and free cash flow of ($0.13B) for 2025 — a FCF margin of —. Capital expenditure was $0.00B.
Frequently asked questions
AVIR · 4 questionsAtea Pharmaceuticals, Inc. generated free cash flow of ($0.13B) for 2025, up 2.6% year-over-year.
AVIR free cash flowFCF margincash flow yield
· Source: FMP /stable/cash-flow-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-10